This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yee, K. W.L. Articles by Giles, F. J. Search for Related Content PubMed PubMed Citation Articles by Yee, K. W.L. Articles by Giles, F. J.

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Authors' Affiliations: ¹ Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, Texas and ² Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Francis J. Giles, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030. Phone: 713-792-8217; Fax: 713-794-4297; E-mail: frankgiles{at}aol.com.

Purpose: ABT-751 is an oral antimitotic agent that binds to the colchicine site on ß-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias.

Study Design: Thirty-two patients were treated: nine with 100 (n = 3), 125 (n = 3), or 150 mg/m² (n = 3) of ABT-751 given orally once daily for 7 days every 3 weeks and 23 with 75 (n = 3), 100 (n = 3), 125 (n = 5), 150 (n = 5), 175 (n = 3), or 200 mg/m² (n = 4) of ABT-751 given orally once daily for 21 days every 4 weeks. Consenting patients had pharmacogenetic sampling and enumeration of circulating endothelial cells (CEC).

Results: Dose-limiting toxicity consisted of ileus in one patient at 200 mg/m², with a subsequent patient developing grade 2 constipation at the same dose level. One patient with relapsed acute myelogenous leukemia achieved a complete remission that was sustained for 2 months. Four other patients had transient hematologic improvements, consisting of a decrease in peripheral blood blasts and improvements in platelet counts. CEC number was reduced in three patients with a concomitant reduction in peripheral blasts. A previously undescribed nonsynonymous single nucleotide polymorphism, encoding Ala¹⁸⁵Thr, was identified in exon 4 of the ß-tubulin gene, TUBB, in three other patients. The recommended phase 2 dose in hematologic malignancies is 175 mg/m² daily orally for 21 days every 4 weeks.

Conclusion: Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted.

This article has been cited by other articles:

				E. Fox, J. M. Maris, B. C. Widemann, W. Goodspeed, A. Goodwin, M. Kromplewski, M. E. Fouts, D. Medina, S. L. Cohn, A. Krivoshik, et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1111 - 1115. [Abstract] [Full Text] [PDF]

				C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Clin. Cancer Res., May 1, 2007; 13(9): 2728 - 2737. [Abstract] [Full Text] [PDF]

				N. Mehra, M. Penning, J. Maas, L. V. Beerepoot, N. van Daal, C. H. van Gils, R. H. Giles, and E. E. Voest Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases. Clin. Cancer Res., August 15, 2006; 12(16): 4859 - 4866. [Abstract] [Full Text] [PDF]

				T. L. Gururaja, D. Goff, T. Kinoshita, E. Goldstein, S. Yung, J. McLaughlin, E. Pali, J. Huang, R. Singh, S. Daniel-Issakani, et al. R-253 disrupts microtubule networks in multiple tumor cell lines. Clin. Cancer Res., June 15, 2006; 12(12): 3831 - 3842. [Abstract] [Full Text] [PDF]

				W. J. van Heeckeren, S. Bhakta, J. Ortiz, J. Duerk, M. M. Cooney, A. Dowlati, K. McCrae, and S. C. Remick Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists? J. Clin. Oncol., April 1, 2006; 24(10): 1485 - 1488. [Full Text] [PDF]